Download programm - livercancer

Monday, 26.05.2014
Time
PIs (speaker in bold)
Project Title
10:00 - 10:15 Welcome and Progress report of the SFB/TRR77 (Schirmacher)
10:15 - 10:29 Bartenschlager, Ralf
Lohmann, Volker
- 10:43 Pietschmann, Thomas
Haid, Sibylle
- 10:57 Herzig, Stephan
Berriel-Diaz, Mauricio
- 11:11 Straub, Beate K.
- 11:25 Wuestefeld, Torsten
- 11:39 Balakrishnan, Asha
- 11:53 Vogel, Arndt
- 12:07 Angel, Peter
Heß, Jochen
- 12:21 Mederacke, Ingmar
Molecular mechanisms of pro-carcinogenic alterations and HCC
development induced by hepatotropic viruses
Hepatitis C virus cell entry factor usage in Hepatitis C progression
and liver carcinogenesis
Characterization of pathways contributing to the metabolic etiology
of HCC
Lipid droplets and associated proteins in chronic liver diseases and
hepatocarcinogenesis
Functional genetic dissection of NASH induced
hepatocarcinogenesis
Interactions between signaling, metabolic pathways and miRNAs in
HCC
Role of c-myc in Chronic Liver Injury and Liver Cancer
Function of HMGB1-RAGE signaling in inflammation-associated liver
carcinogenesis
Role of hepatic stellate cells in liver metastasis
12:30 - 13:30 Lunch break
- 13:44 Schulze-Osthoff, Klaus
Hailfinger, Stephan
- 13:58 Breuhahn, Kai
- 14:12 Longerich, Thomas
Pellegrino, Rossella
- 14:26 Malek, Nisar
Role of atypical nuclear IκB proteins in HCC formation
Gain of function mechanisms of transcriptional regulators in tumor
initiation and progression
Protumorigenic function of EEF1A2 in human HCC
Role of centrosome duplication defects in the pathogenesis of HCC
- 14:40 Singer, Stephan
Nuclear pore complex (NPC) composition in hepatocarcinogenesis
- 14:54 Nordheim, Alfred
- 15:08 Rössler, Stephanie
Mechanisms of HCC tumor suppression
Tumor suppressor genes in human hepatocellular carcinoma: Link
to inflammation
Functional consequences of epigenetic regulated tumour
suppressor miRNA-449 family in HCC
- 15:22 Skawran, Britta
Schlegelberger, Brigitte
15:25 - 15:50 Coffee break
- 16:04 Bitzer Michael
Salih, Helmut R.
- 16:18 Kossatz-Böhlert, Uta
- 16:32
- 16:46
- 17:00
- 17:24
17:30 - 18:30
Epigenetic priming of liver tumors for induction of NK cell immunity
Functional and phenotypic regulators of hepatic progenitor cells in
dependence of the mTORC1 kinase complex
Longerich, Thomas
Comprehensive characterization of HCC-CC
Bermejo, Justo Lorenzo Integrative assessment of epigenetic and genetic changes in
gallbladder cancer development
Goeppert, Benjamin
Genetic and epigenetic characterization of cholangiocarcinoma
Weichenhan, Dieter
Zender, Lars
Induction of hepatocyte - cholagiocyte transdifferentiation as a
Zieker, Derek
therapeutic strategy to treat bile duct disease
Report of the gerok stipends (Geraud (i.A. Koch), Holzer, Goeppert, Waldburger)
18:30 - 19:30 SFB/TRR77 key structure status and perspective
19:30h
Dinner
Tuesday, 27.05.2014
Time
PIs (speaker in bold)
Project Title
7:30 – 8:30 Breakfast; Steering Committee meeting
8:30 - 8:44 Bantel, Heike
Lehner, Frank
Schulze-Osthoff, Klaus
- 8:58 Dooley, Steven
Ebert, Matthias
Meindl-Beinker, Nadja
Hopf, Carsten
- 9:12 Wirth, Thomas
- 9:26 Lauer, Ulrich M.
- 9:40 Woller, Norman
- 9:54 Gürlevik, Engin
- 10:08 Kühnel, Florian
Kubicka, Stefan
- 10:22 Yevsa, Tetyana
- 10:36 Goerdt, Sergeij
Augustin, Hellmut
- 10:50 Saborowski, Anna
Saborowski, Michael
Tumor-targeted TRAIL fusion proteins as novel treatment strategy
for hepatocellular carcinoma
TGF- signaling (inhibition) on targeted treatment response in HCC
TGF- signaling (inhibition) on targeted treatment response in HCC
Development of co-stimulation assisted T cell vaccinations for the
therapy of liver cancers
Signaling Pattern Virograms (SPV) for personalization &
optimization of HCC Virotherapy
Enhancement of systemic neo-epitope (mutanom) responsiveness
of cytotoxic T cells by interference of localized oncolytic infection
and tumor vaccination.
Immunoepitope dynamics in liver cancer during resection, dormancy and recurrence as a basis for tailored tumor therapies
Targeting the mutanome of HCC by viral inflammation and tumordirected vaccinations: a model for individualized tumor therapy
Investigation of therapy‐induced senescence and concomitant
immune response in metastatic liver cancer (model)
HCC and the hepatic vascular niche: Analysis of angiocrine and
adhesive vascular targets
A negative selection shRNA screen for targeted combination
therapy in cholangiocarcinoma
10:50 - 11:10 Coffee break and group picture
11:10 - 12:10 Relaunch: structure, timeline, discussion
12:10 - 13:10 Further HCC activities
- 13:15 Closing remarks
Lunch break and Steering Committee meeting